Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 313

1.

Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic.

Citrome L.

Int J Clin Pract. 2011 Feb;65(2):189-210. doi: 10.1111/j.1742-1241.2010.02587.x. Epub 2010 Dec 3. Review.

PMID:
21129135
2.

Iloperidone for schizophrenia: a review of the efficacy and safety profile for this newly commercialised second-generation antipsychotic.

Citrome L.

Int J Clin Pract. 2009 Aug;63(8):1237-48. doi: 10.1111/j.1742-1241.2009.02142.x. Review.

PMID:
19624791
3.

Asenapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic.

Citrome L.

Int J Clin Pract. 2009 Dec;63(12):1762-84. doi: 10.1111/j.1742-1241.2009.02228.x. Epub 2009 Oct 14. Review.

PMID:
19840150
4.

Lurasidone for schizophrenia: a brief review of a new second-generation antipsychotic.

Citrome L.

Clin Schizophr Relat Psychoses. 2011 Jan;4(4):251-7. doi: 10.3371/CSRP.4.4.5. Review.

PMID:
21177242
5.

Lurasidone for schizophrenia: what's different?

Kantrowitz JT, Citrome L.

Expert Rev Neurother. 2012 Mar;12(3):265-73. doi: 10.1586/ern.12.7. Review.

PMID:
22364325
6.
7.

Lurasidone in schizophrenia: new information about dosage and place in therapy.

Citrome L.

Adv Ther. 2012 Oct;29(10):815-25. doi: 10.1007/s12325-012-0052-6. Epub 2012 Sep 20. Review.

PMID:
23001538
10.

Aerosolised antipsychotic assuages agitation: inhaled loxapine for agitation associated with schizophrenia or bipolar disorder.

Citrome L.

Int J Clin Pract. 2011 Mar;65(3):330-40. doi: 10.1111/j.1742-1241.2010.02615.x. Epub 2010 Dec 29. Review.

PMID:
21199198
12.

Clinical assessment of lurasidone benefit and risk in the treatment of bipolar I depression using number needed to treat, number needed to harm, and likelihood to be helped or harmed.

Citrome L, Ketter TA, Cucchiaro J, Loebel A.

J Affect Disord. 2014 Feb;155:20-7. doi: 10.1016/j.jad.2013.10.040. Epub 2013 Oct 28. Review.

PMID:
24246116
13.

Inhaled loxapine for agitation revisited: focus on effect sizes from 2 Phase III randomised controlled trials in persons with schizophrenia or bipolar disorder.

Citrome L.

Int J Clin Pract. 2012 Mar;66(3):318-25. doi: 10.1111/j.1742-1241.2011.02890.x. Epub 2012 Jan 9. Review.

PMID:
22226343
14.

Lurasidone: a clinical overview.

Kane JM.

J Clin Psychiatry. 2011;72 Suppl 1:24-8. doi: 10.4088/JCP.10075su1.05. Review.

15.

Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis.

De Hert M, Yu W, Detraux J, Sweers K, van Winkel R, Correll CU.

CNS Drugs. 2012 Sep 1;26(9):733-59. doi: 10.2165/11634500-000000000-00000. Review.

PMID:
22900950
16.

Lurasidone: an atypical antipsychotic for schizophrenia.

Risbood V, Lee JR, Roche-Desilets J, Fuller MA.

Ann Pharmacother. 2012 Jul-Aug;46(7-8):1033-46. doi: 10.1345/aph.1M721. Epub 2012 Jul 24. Review.

PMID:
22828971
17.

Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial.

Nakamura M, Ogasa M, Guarino J, Phillips D, Severs J, Cucchiaro J, Loebel A.

J Clin Psychiatry. 2009 Jun;70(6):829-36. doi: 10.4088/JCP.08m04905. Epub 2009 Jun 2.

PMID:
19497249
20.

A review of published evidence reporting on the efficacy and pharmacology of lurasidone.

McIntyre RS, Cha DS, Alsuwaidan M, McIntosh D, Powell AM, Jerrell JM.

Expert Opin Pharmacother. 2012 Aug;13(11):1653-9. doi: 10.1517/14656566.2012.683174. Epub 2012 May 5. Review.

PMID:
22559286

Supplemental Content

Support Center